Background {#Sec1}
==========

*Pneumocystis* is an opportunistic fungal pathogen that causes *Pneumocystis jirovecii* pneumonia (PJP). PJP-related morbidity and mortality appear to be a major health problem for patients with acquired immunodeficiency syndrome (AIDS) and for those with immunosuppression resulted from chemotherapy, organ transplantation and long-term treatment with steroid or other immunosuppressants for a variety of diseases \[[@CR1]\]. The clinical features, radiological findings, response to treatment and outcome of PJP are reported to be widely different between the patients with or without AIDS \[[@CR2], [@CR3]\]. The reasons underlying the differences in clinical features, radiological findings, treatment response and outcome of PJP between the patients with and without AIDS remain to be elucidated.

Some studies suggest that pathology of PJP inflammatory response is the main factor attributed to morbidity and mortality of PJP patients \[[@CR4]--[@CR8]\], although pathology itself and underlying disorders resulting in impaired immune function are also of clinical importance. Our and previous studies \[[@CR9], [@CR10]\] indicated that immune dysregulation was found in PJP of the patients with AIDS and non-AIDS, and certain pro-inflammatory cytokine/anti-inflammatory cytokine ratios in bronchoalveolar lavage fluid (BALF) were of considerable value in assessing the severity of PJP and outcome of the patients \[[@CR10]\].

Mixed pulmonary infections including PJP and other pathogens are uncommon in patients with AIDS or non-AIDS immunocompromised hosts. In this study, we intended to explore the impact of concomitant pulmonary infection on immune dysregulation of PJP as evidenced by the changes in pro-inflammatory cytokines and anti-inflammatory cytokines and its clinical relevance. Our study results showed concurrent pulmonary infection might enhance immune dysregulation of PJP in non-AIDS immunocompromised patients, but did not affect the outcome as evidenced by morbidity and mortality.

Methods {#Sec2}
=======

Non-AIDS PJP patients {#Sec3}
---------------------

Sixty five consecutive non-AIDS immunocompromised patients with PJP diagnosed by identification of *Pneumocystis jirovecii* cysts or trophozoites in Papanicolaou- and Gomori methenamine silver stained-smears of BALF at Taipei Veterans General Hospital from November 1987 to September 2012 were included for this study. The patients were classified into two groups. One group included patients with pure PJP. The other group included those with PJP and concomitant pulmonary infection including cytomegalovirus (CMV) pneumonia and/or co-infections with other pathogens. Peripheral blood samples were collected after bronchoalveolar lavage (BAL) for measurements of cytokines and inflammatory biomarkers. The institutional Review Board of Taipei Veterans General Hospital approved the study (No: 201009019IC and No: 96-04-02A), and written informed consent was obtained from all patients before entering the study of cytokines and inflammatory biomarkers in BALF and blood.

Diagnostic criteria {#Sec4}
-------------------

Bacterial pneumonia was diagnosed when a quantitative bacterial culture from BALF samples grew pathogenic bacteria \>10^4^ colonies/mL. CMV was considered to be the pathogen if it was demonstrated on BALF cytology smears or positive result of CMV culture from BALF. Fungal pneumonia was diagnosed when one of the following criteria was met: (1) fungi were identified by microbiologic studies in at least two different lower respiratory tract secretions including BALF; (2) fungi were demonstrated by cytology smears of BALF in the presence of a compatible clinical and chest imaging findings; (3) fungi were demonstrated by histopathological examination of lung biopsy specimens; (4) positive results of blood cultures in the presence of compatible clinical and chest imaging features. Legionella infection was considered when single serum indirect fluorescent antibody titer was ≧1:256.

Oxygenation index {#Sec5}
-----------------

The arterial oxygen tension (PaO~2~) was analyzed with ABL III (Radiometer, Copenhagen, Denmark). Oxygenation index (PaO~2~/FiO~2~ ratio) was calculated as PaO~2~ divided by inspired oxygen fraction (FiO~2~).

BALF and blood samples {#Sec6}
----------------------

The fiberoptic bronchoscope (Model BF20 or P20; Olympus, Tokyo, Japan) was wedged in the orifice of a lobar or segmental bronchus of the right middle lobe or lingular division or other appropriate location. Diagnostic BAL was done using three aliquots of a 50-mL sterile isotonic sodium chloride. Aspirates were pooled into a siliconized container and kept on ice during transport. Part of the retrieved BALF was subjected to Papanicolaou and Riu's staining routinely. Some slides were stored for subsequent special staining if clinically indicated. A 10-mL sample of venous blood was drawn immediately after BAL. The supernatants of blood and BALF were frozen and stored at -70°C until analyzed.

BALF cell analysis {#Sec7}
------------------

BALF for cell analysis was filtered through two-layer sterile gauzes to remove mucus, and then cellular materials were sedimented by centrifugation (2500 rpm for 10 min at 4°C) and the supernatant was stored at -70°C for cytokine analysis later. The pellet was re-suspended in 1 ml phosphate buffered saline (PBS) for quantitative cell count. The cell differentials of BALF were measured by a hemocytometer (Hausser Scientific, Horsham, PA, USA) for counting at least 200 cells. For analysis of lymphocyte subpopulations 200 μl of cell suspensions (2×10^6^ cells) were incubated for 40 min at 4°C with 20 ml fluorescein isothiocyanate conjugated monoclonal antibody (Becton Dickinson, San Jose, Ca, USA). Following the incubation, 2 ml of cold PBS was added to the pellet and washed at 2500 rpm for 10 min at 4°C. Prepared BALF samples were examined by flow cytometry (FACS Calibur, Becton Dickinson, San Jose, CA, USA).

Measurement of cytokines and biomarkers {#Sec8}
---------------------------------------

The levels of cytokines in the supernatants of BALF and blood were measured by the commercially available enzyme-linked immunosorbent assay kits: interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-8, monocyte chemoattractant protein (MCP)-1, IL-17, IL-10 and transforming growth factor (TGF)-β1, and IL-1 receptor antagonist (IL-1RA) (R&D Systems; Minneapolis, MN, USA). The levels of biomarkers in the supernatantsof BALF and blood were determined by commercial enzyme-linked immunosorbent assay kits according to the manufacturer's instructions: high mobility group box 1 (HMGB1, HMGB1 ELISA kit II; Shino-Test Corporation, Tokyo); Krebs von den Lungen-6 (KL-6, Eisai, Tokyo, Japan); receptor for advanced glycation end product (RAGE, R&D Systems; Minneapolis, MN, USA); advanced glycation end product (AGE, Cell Biolabs Inc., San Diego, CA, USA); surfactant protein D (SPD, Biovendor, Modrice, Czech Republic). The lower limits of these variables were adapted as follows: IL-1β, 1 pg/ml; TNF-α, 4.4 pg/ml; IL-8, 3.5 pg/ml; IL-17, 15 pg/ml; MCP-1, 5.0 pg/ml; IL-10, 3.9 pg/ml; TGF-β1, 4.61 pg/ml; IL-1RA, 6.3 pg/ml; SPD, 0.2 ng/ml; HMGB-1, 1 ng/ml; RAGE, 4.12 pg/ml and KL-6, 201 U/ml.

Estimating number of *Pneumocystis jirovecii*fungus in the lung {#Sec9}
---------------------------------------------------------------

This technique was developed by Baughman and his coworkers \[[@CR11]\]. Briefly, the BALF specimens 400 ul were spun onto glass slides, using a cytocentrifuge (Cytospin; Shandon Southern Instruments, Sewickley, PA, USA). The slides were air dried and then stained with Riu's stain (modified May-Giemsa stain). The fungal load was semi-quantitatively measured by counting the number of clusters of *Pneumocystis jirovecii* in relation to 500 nucleated cells per slide.

Measurement of β-D-glucan {#Sec10}
-------------------------

The concentration of β-D-glucan was measured by Fungitell assay. It was performed according to the protocol supplied by the manufacturer (Associates of Cape Cod, MA, USA).

Statistical analysis {#Sec11}
--------------------

Data were expressed as mean and SD or median and interquartile range (IQR), where appropriate. Non-parametric tests were used to analyze the variables because most of them were not normally distributed. Comparisons of the continuous variables between pure PJP and mixed PJP patients were made using the Mann--Whitney U test. Comparisons of the variables in pure PJP patients who were subdivided into two groups based on the variables including oxygenation index, the use of ventilator or survivor status were made using the Mann--Whitney U test. Multivariate analysis was performed using stepwise logistic regression analysis. Comparison for categorical variables between two groups was examined using Chi-squared test and/or Fisher exact, when appropriate. Significance was defined as p \<0.05. Statistical analysis was performed using SPSS version 13 (SPSS, Chicago, IL, USA).

Results {#Sec12}
=======

Demographic characteristics, clinical features and cell profiles in BALF {#Sec13}
------------------------------------------------------------------------

The demographic characteristics and clinical data of 65 non-AIDS patients. With PJP divided into two groups are shown in Table [1](#Tab1){ref-type="table"}. The oxygenation index, Acute Physiology and Chronic Health Evaluation II scores, intensive care unit (ICU) length of stay, the percentage of ICU admission, use of ventilator and death showed no significant differences between the pure PJP and mixed PJP patients. The concurrent pulmonary infections included bacteria in four cases, aspergillus in one case, CMV in nine cases, cryptococcus in two cases, CMV and aspergillus in one case, and CMV and legionella spp. in one case. The total cell count and cell differentials, and lymphocyte subpopulations in BALF are summarized in Table [2](#Tab2){ref-type="table"}. There were no significant differences in total cell count, cell differentials and lymphocyte subpopulations between PJP patients with and without concurrent pulmonary infection.Table 1**Demographic and clinical characteristics of 65 patients with PJP**Pure PJPMixed PJPP valueGender(M/F)25/229/90.818Age, years49.1 ± 16.050.6 ± 17.70.587Underlying diseases  Hematological malignancy s/p chemotherapy62  Allogeneic peripheral blood stem cell transplantation32  Solid organ transplantation (kidney/heart/liver/pancreas/pancreas-kidney)19/4/2/1/13/0/0/0/0  Connective tissue diseases with immunosuppresants62  Glomerulonephritis with immunosuppresants36  Prostate cancer with immunosuppresants10  Breast cancer with immunosuppresants01  Long-term steroid therapy11  DM01PaO~2~/FiO~2~ before BAL230.0(182.2;278.7)245.4(158.3;322.9)0.631APACHE II scores23.00(18.00;27.50)23.50(20.25;26.50)0.987ICU admission, case number (%)23(48.9)12(66.7)0.269ICU length of stay (days)19.0(7.3;24.0)11.0(6.3;21.3)0.456Ventilator needed, case number (%)24(51.1)11(61.1)0.667Death, case number (%)19(40.4)10(55.6)0.403Data are expressed as case number and % in parenthesis or median IQR (25%;75%).PJP = *Pneumocystis jirovecii* pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections; PaO~2~ = arterial oxygen tension; FiO~2~ = fraction of inspired oxygen; ICU = intensive care unit; BAL = bronchoalveolar lavage; APACHE = Acute Physiology and Chronic Health Evaluation.Table 2**Comparisons of cell profile and lymphocyte subpopulations in BALF between pure and mixed PJP patients**Pure PJP (N =47)Mixed PJP (N =18)P valueTotal cell count, 10^3^/ml46.00(21.24;95.16)30.00(18.27;115.07)0.560Macrophages, %67.50(57.00;82.00)64.25(42.63;71.38)0.246Macrophage count, 10^3^/ml36.23(12.64;53.01)18.88(10.19;60.15)0.519Lymphocytes, %10.25(3.00;29.63)7.50(1.88;20.38)0.364Lymphocyte count, 10^3^/ml3.39(1.18;17.04)2.03(1.01;3.47)0.283Neutrophils, %10.50(4.88;20.88)21.50(9.13;33.13)0.06Neutrophil count, 10^3^/ml3.97(1.84;11.41)7.84(1.46;25.07)0.386CD4/CD8 ratio22.30(8.50;37.40)11.50(4.80;22.63)0.127CD4+ cells, %2.48(0.30;8.02)0.42(0.06;5.73)0.302CD4+ cells, 10^3^/ml31.80(15.80;59.70)16.85(8.28;51.48)0.384CD8+ cells, %4.67(0.55;13.19)0.51(0.21;19.01)0.356CD8+ cells, 10^3^/ml0.67(0.31;1.20)0.31(0.18;1.95)0.384Data are expressed as median IQR (25%;75%).BALF = Bronchoalveolar lavage fluid; PJP = *Pneumocystis jirovecii* pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections.The comparison was made by Mann--Whitney U test.

Comparisons of BALF and blood cytokines between pure and mixed PJP patients {#Sec14}
---------------------------------------------------------------------------

The blood IL-1β was not measured because of being undetectable or very low levels based on our previous experience. Comparisons of cytokines in BALF and blood samples between pure PJP and mixed PJP patients are given in Table [3](#Tab3){ref-type="table"}. The levels of BALF anti-inflammatory cytokines including IL-10, TGF-β1 and IL-1RA showed no significant differences between the two groups.Table 3**Comparisons of cytokines in BALF and blood between pure and mixed PJP patients**Pure PJP (N =47)Mixed PJP (N =18)P value**BALF**  IL-1β, pg/ml2.13(1.66;2.91)4.59(1.92;24.45)0.024  TNF-α, pg/ml10.10(8.83;13.08)12.24(10.09;23.84)0.026  IL-8, pg/ml46.30(31.80;175.30)298.85(110.98;434.63)0.001  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.883  MCP-1, pg/ml1048.50(250.81;2842.70)1140.25(459.46;2171.44)0.649  IL-10, pg/ml3.90(3.90;7.70)3.90(3.90;3.90)0.152  TGF-β1, pg/ml49.60(42.10;60.30)46.55(44.88;59.33)0.899  IL-1RA, pg/ml1177.95(609.10;2816.00)1682.15(1174.78;4496.43)0.257  IL-1β/IL-100.48(0.35;0.56)1.18(0.29;5.22)0.018  TNF-α/IL-102.33(1.26;2.64)2.80(2.43;3.87)0.011  IL-8/IL-1010.21(4.69;29.44)53.60(24.49;85.10)0.001  IL-17/IL-103.85(3.17;3.85)3.85(3.85;3.85)0.698  MCP-1/ IL-10214.87(55.52;362.63)176.11(117.81;375.97)0.567  IL-1β/TGF-β10.04(0.02;0.05)0.11(0.03;0.42)0.002  TNF-α/TGF-β10.19(0.11;0.25)0.25(0.22;0.39)0.004  IL-8/TGF-β10.76(0.28;2.22)4.85(2.47;9.99)\<0.001  IL-17/TGF-β10.31(0.26;0.37)0.27(0.25;0.36)0.570  MCP-1/TGF-β110.48(0.96;42.87)18.54(10.85;39.91)0.182  IL-1β/IL-1RA0.00(0.00;0.00)0.01(0.00.0.02)0.048  TNF-α/IL-1RA0.01(0.00;0.02)0.01(0.00;0.02)0.743  IL-8/IL-1RA0.06(0.02;0.22)0.11(0.05;0.76)0.385  IL-17/IL-1RA0.01(0.01;0.03)0.01(0.00;0.02)0.385  MCP-1/IL-1RA0.99(0.23;1.52)0.65(0.08;1.59)0.905**Blood**  TNF-α, pg/ml12.00(9.00;17.10)12.25(7.55;20.68)0.829  IL-8, pg/ml30.41(18.78;53.40)71.80(32.90;136.33)0.008  IL-17, pg/ml15.00(15.00; 15.00)15.00(15.00; 15.00)0.832  MCP-1, pg/ml1271.70(402.90;2229.20)1928.80(525.95;3496.50)0.285  IL-10, pg/ml19.90(10.40;37.50)33.90(9.88;62.53)0.226  TGF-β1, pg/ml458.20(245.89;7768.70)5996.50(259.08;7819.45)0.288  IL-1RA, pg/ml884.00(354.68;2348.75)2160.40(402.80;6116.50)0.229  IL-8/IL-101.73(0.86;2.79)2.38(0.92;6.05)0.131  IL-8/TGF-β10.06(0.00;0.21)0.01(0.00;0.30)0.895  TNF-α/IL-100.56(0.35;1.12)0.35(0.19;1.19)0.284  TNF-α/TGF-β10.02(0.00;0.07)0.00(0.00;0.07)0.215Data are expressed as median IQR (25%;75%).BALF = Bronchoalveolar lavage fluid; PJP = *Pneumocystis jirovecii* pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.The comparison was made by Mann--Whitney U test.

The values of BALF IL-1β, TNF-α, IL-8 and the ratios of IL-1β/IL-10, TNF-α/IL-10, IL-8/IL-10, IL-1β/TGF-β1, TNF-α/TGF-β1, IL-8/TGF-β1 and IL-1β/IL-1RA were significantly higher in mixed PJP than in pure PJP patients. The blood levels of IL-8 were significantly higher in mixed PJP than those in pure PJP patients.

Comparisons of BALF and blood inflammatory biomarkers between pure and mixed PJP patients {#Sec15}
-----------------------------------------------------------------------------------------

No significant differences in the inflammatory biomarkers levels in BALF or blood were observed when pure PJP were compared with mixed PJP patients. The biomarkers included KL-6, SPD, HMGB-1, RAGE and AGE. The results are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Comparisons of cytokines and cytokine ratios in BALF and blood between concurrent bacterial and viral infection in mixed PJP patients {#Sec16}
-------------------------------------------------------------------------------------------------------------------------------------

We compared pro-inflammatory cytokines, anti-inflammatory cytokines and ratio of pro-inflammatory cytokines/anti-inflammatory cytokines in both BALF and blood in mixed PJP patients who were divided into concurrent pulmonary bacterial and viral infection groups. The results showed no significant differences in the variables measured except for that BALF IL-1β/IL-1RA ratio were significantly higher in bacterial infection group. The results are shown in Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Comparisons of *Pneumocystis jirovecii*burden in the lung {#Sec17}
---------------------------------------------------------

The median number of *Pneumocystis jirovecii* in the lung was 3 (IQR, 1;7) in pure PJP and 2.5 (IQR, 1;12) in mixed PJP patients. There was no significant difference between the two groups. The median levels of BALF β-D-glucan in pure and mixed PJP patients were 203.30 (IQR, 148.30;442.40) and 260.60 (IQR, 134.40;623.40), respectively. The median levels of serum β-D-glucan in pure and mixed PJP patients were 213.00 (IQR, 19.90;784.50) and 215.65 (IQR, 75.45;7103.00), respectively. The values of BALF and serum β-D-glucan were not significantly different between the two groups.

Comparisons of cytokines and pro-inflammatory/anti-inflammatory cytokine ratios between pure PJP patients divided into groups by oxygenation index (PaO~2~/FiO~2~), the use of ventilator and outcome {#Sec18}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comparisons between pure PJP patients with PaO~2~/FiO~2~ \> 200 mmHg and PaO~2~/FiO~2~ ≤ 200 mmHg are shown in Table [4](#Tab4){ref-type="table"}. Compared to the patients with PaO~2~/FiO~2~ \> 200 mmHg, those with PaO~2~/FiO~2~ ≤ 200 mmHg had significantly higher BALF levels of IL-1RA, ratios of IL-1β/TGF-β1, TNF-α/TGF-β1, IL-8/TGF-β1 and MCP-1/TGF-β1, and had significantly higher blood levels of TGF-β1 and ratios of IL-8/IL-10 and TNF-α/IL-10. The ratios of IL-8/TGF-β1 and TNF-α/TGF-β1 in blood was significantly lower in those with PaO~2~/FiO~2~ ≤ 200 mmHg. However, after stepwise logistic regression analysis, none of these variables was independent factor.Table 4**Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between pure PJP patients with PaO** ~**2**~ **/FiO** ~**2**~  **≤ 200 and \>200 mmHg**PaO ~2~/FiO ~2~\>200 mmHg(N =24)PaO ~2~/FiO ~2~ ≤ 200 mmHg(N =9)P value\*P value ^\#^**BALF**  IL-1β, pg/ml2.24(1.85;2.86)2.65(2.00;5.32)0.414  TNF-α, pg/ml10.09(7.82;12.44)13.08(9.52;17.82)0.154  IL-8, pg/ml48.40(24.38;168.25)175.30(35.00;342.90)0.193  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.645  MCP-1, pg/ml1066.50(663.37;2593.31)2453.16(715.00;4288.47)0.254  IL-10, pg/ml4.25(3.90;8.93)3.90(3.90;8.12)0.414  TGF-β1, pg/ml53.40(45.45;128.30)43.90(42.10;51.70)0.150  IL-1RA, pg/ml709.70(463.30;1730.20)1835.20(929.33;2816.00)0.0450.144  IL-1β/IL-100.41(0.29;0.57)0.54(0.40;1.36)0.238  TNF-α/IL-102.33(1.19;2.63)2.44(2.06;3.50)0.179  IL-8/IL-108.83(3.67;32.04)28.22(8.78;53.10)0.166  IL-17/IL-103.85(2.84;3.85)3.85(2.42;3.85)0.547  MCP-1/ IL-10220.15(110.95;334.84)629.02(170.28;914.57)0.131  IL-1β/TGF-β10.03(0.01;0.05)0.06(0.03;0.13)0.0260.741  TNF-α/TGF-β10.16(0.03;0.22)0.23(0.22;0.37)0.0030.421  IL-8/TGF-β10.63(0.16;1.84)3.26(0.80;7.94)0.0320.787  IL-17/TGF-β10.29(0.27;0.33)0.36(0.29;0.38)0.121  MCP-1/TGF-β114.13(4.40;34.32)58.27(13.32;107.14)0.0320.158  IL-1β/IL-1RA0.00(0.00;0.01)0.00(0.00;0.00)0.210  TNF-α/IL-1RA0.02(0.01;0.04)0.01(0.00;0.01)0.121  IL-8/IL-1RA0.18(0.02;0.99)0.07(0.02;0.12)0.374  IL-17/IL-1RA0.02(0.01;0.03)0.01(0.01;0.02)0.140  MCP-1/IL-1RA0.99(0.24;4.05)1.48(0.46;1.52)0.750**Blood**  TNF-α, pg/ml14.50(10.60;17.50)12.70(8.50;24.20)0.640  IL-8, pg/ml33.81(18.85;78.35)41.20(21.60;90.55)0.766  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.643  MCP-1, pg/ml1557.80(792.83;2655.05)1382.60(318.75;2337.80)0.512  IL-10, pg/ml33.40(12.25;56.93)20.80(9.65;32.95)0.111  TGF-β1, pg/ml255.15(168.10;3908.20)3479.90(1020.85;10050.65)0.0140.892  IL-1RA, pg/ml1087.90(297.10;2697.80)701.80(286.90;2375.60)0.938  IL-8/IL-101.22(0.59;1.76)2.79(1.14;4.14)0.0200.903  IL-8/TGF-β10.12(0.04;0.48)0.02(0.01;0.04)0.0200.787  TNF-α/IL-100.35(0.17;0.93)0.72(0.43;1.34)0.0350.872  TNF-α/TGF-β10.07(0.02;0.24)0.00(0.00;0.03)0.0120.233Data are expressed as median IQR (25%;75%).PaO~2~/FiO~2~ = arterial oxygen tension/fraction of inspired oxygen; BALF = Bronchoalveolar lavage fluid; PJP = *Pneumocystis jirovecii* pneumonia; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.The comparison was made by Mann--Whitney U test.P\*: univariate analysis, P^\#^: multivariate analysis.

Compared with pure PJP patients without ventilator, BALF levels of IL-8 were significantly higher and the values of IL-10 were markedly lower in pure PJP patients with ventilator. BALF ratios of IL-8/IL-10, IL-1β/TGF-β1, TNF-α/TGF-β1, IL-8/TGF-β1, MCP-1/TGF-β1 and MCP-1/IL-1RA, and blood levels of IL-8 and IL-10 and were significantly higher in pure PJP patients with ventilator. The TNF-α/IL-10 ratio in blood was significantly lower in those with ventilator (Table [5](#Tab5){ref-type="table"}). However, after stepwise logistic regression analysis, only BALF IL-8 was the independent factor (p =0.023, 95% confident interval \[CI\] =0.000-0.004).Table 5**Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between pure PJP patients with and without ventilator**Without ventilator (N =22)With ventilator (N =25)P value\*P value ^\#^**BALF**  IL-1β, pg/ml2.23(1.73;2.91)2.10(1.53;3.46)0.915  TNF-α, pg/ml9.81(7.23;14.31)10.30(9.09;12.84)0.332  IL-8, pg/ml35.63(22.28;70.59)59.90(32.95;249.65)0.0230.043  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.876  MCP-1, pg/ml847.20(114.46;3158.55)1048.50(326.90;2761.43)0.565  IL-10, pg/ml5.33(3.90;9.25)3.90(3.90;5.50)0.0490.954  TGF-β1, pg/ml53.40(42.10;707.20)48.80(42.10;55.10)0.203  IL-1RA, pg/ml1323.10(566.70;3432.50)1142.20(632.70;2303.10)0.678  IL-1β/IL-100.39(0.26;0.55)0.49(0.37;0.57)0.119  TNF-α/IL-102.23(1.11;2.58)2.51(2.06;2.71)0.098  IL-8/IL-107.24(3.31;12.42)15.36(8.26;48.67)0.0040.733  IL-17/IL-103.85(3.12;3.85)3.85(2.84;3.85)0.981  MCP-1/ IL-10103.17(28.60;402.18)262.10(74.72;397.89)0.172  IL-1β/TGF-β10.03(0.00;0.05)0.04(0.03;0.07)0.0180.545  TNF-α/TGF-β10.13(0.01;0.25)0.21(0.18;0.26)0.0170.321  IL-8/TGF-β10.47(0.07;1.02)1.35(0.73;5.61)\<0.0010.707  IL-17/TGF-β10.29(0.08;0.46)0.31(0.27;0.36)0.793  MCP-1/TGF-β15.13(0.50;36.72)21.51(5.32;56.99)0.0230.369  IL-1β/IL-1RA0.00(0.00;0.01)0.00(0.00;0.00)0.649  TNF-α/IL-1RA0.01(0.00;0.02)0.01(0.00;0.02)0.756  IL-8/IL-1RA0.03(0.01;0.08)0.10(0.02;0.40)0.126  IL-17/IL-1RA0.02(0.00;0.03)0.01(0.01;0.03)0.943  MCP-1/IL-1RA0.24(0.03;0.70)1.47(0.28;1.85)0.0110.582**Blood**  TNF-α, pg/ml9.90(8.30;17.10)12.45(10.20;17.15)0.123  IL-8, pg/ml22.30(14.23;40.75)42.70(22.95;105.15)0.0040.969  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.866  MCP-1, pg/ml931.65(368.58;1719.33)1382.60(459.80;2485.55)0.354  IL-10, pg/ml11.21(9.33;21.60)32.90(13.35;47.25)0.0060.938  TGF-β1, pg/ml260.35(225.00;11506.09)557.50(269.85;5782.80)0.898  IL-1RA, pg/ml2114.30(693.50;3696.90)701.80(286.90;2117.70)0.169  IL-8/IL-101.83(0.80;2.61)1.71(0.94;2.81)0.966  IL-8/TGF-β10.04(0.00;0.15)0.10(0.01;0.23)0.159  TNF-α/IL-101.10(0.65;1.31)0.45(0.25;0.74)0.0220.160  TNF-α/TGF-β10.00(0.00;1.80)0.03(0.00;0.07)0.540Data are expressed as median IQR (25%;75%).BALF = Bronchoalveolar lavage fluid; PJP = *Pneumocystis jirovecii* pneumonia; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.The comparison was made by Mann--Whitney U test.P\*: univariate analysis, P^\#^: multivariate analysis.

Similar findings could be found in pure PJP patients who were divided into subgroups by clinical outcome. Compared with survivors, the non-survivors had significantly higher BALF values of IL-8 and ratios of IL-8/IL-10, IL-1β/TGF-β1, IL-8/TGF-β1, MCP-1/TGF-β1, IL-8/IL-1RA and MCP-1/IL-1RA, and significantly higher blood levels of IL-10 and IL-8. The blood level of IL-1RA was significantly lower in non-survivors (Table [6](#Tab6){ref-type="table"}). However, after stepwise logistic regression analysis, only BALF IL-8/TGF-β1 was the independent factor (p =0.018, 95% CI =0.022-0.186).Table 6**Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between survivors and non-survivors of pure PJP patients**Survivor (N =28)Non-survivor (N =19)P value\*P value ^\#^**BALF**  IL-1β, pg/ml2.21(1.68;3.51)2.00(1.50;2.91)0.948  TNF-α, pg/ml10.07(7.98;14.05)10.10(9.07;11.60)0.761  IL-8, pg/ml35.63(22.60;79.26)114.80(36.70;375.60)0.0100.694  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.751  MCP-1, pg/ml736.49(218.78;2703.81)1065.50(344.00;3069.70)0.474  IL-10, pg/ml4.61(3.90;8.89)3.90(3.90;4.40)0.079  TGF-β1, pg/ml53.40(43.00;194.80)48.80(41.20;54.13)0.094  IL-1RA, pg/ml1589.90(669.20;3178.55)1077.40(512.40;1870.50)0.254  IL-1β/IL-100.41(0.28;0.56)0.49(0.36;0.57)0.293  TNF-α/IL-102.33(1.15;2.63)2.51(2.20;2.71)0.193  IL-8/IL-108.26(3.66;13.75)17.79(8.90;54.86)0.0020.735  IL-17/IL-103.85(3.48;3.85)3.85(2.27;3.85)0.451  MCP-1/ IL-10112.85(39.67;334.84)273.21(79.44;433.15)0.146  IL-1β/TGF-β10.03(0.00;0.05)0.04(0.03;0.06)0.0420.611  TNF-α/TGF-β10.15(0.01;0.26)0.21(0.18;0.25)0.091  IL-8/TGF-β10.51(0.13;1.03)1.56(0.71;7.73)0.0010.018  IL-17/TGF-β10.28(0.23;0.41)0.31(0.27;0.36)0.505  MCP-1/TGF-β16.09(0.54;39.10)21.57(5.49;58.27)0.0440.486  IL-1β/IL-1RA0.00(0.00;0.00)0.00(0.00;0.01)0.451  TNF-α/IL-1RA0.01(0.00;0.02)0.01(0.00;0.02)0.354  IL-8/IL-1RA0.04(0.01;0.09)0.12(0.03;0.53)0.0330.517  IL-17/IL-1RA0.01(0.00;0.03)0.01(0.01;0.03)0.591  MCP-1/IL-1RA0.28(0.18;1.14)1.48(0.46;4.43)0.0120.329**Blood**  TNF-α, pg/ml11.10(8.56;18.20)13.35(10.03;16.45)0.335  IL-8, pg/ml23.65(16.53;41.55)47.10(26.80;136.60)0.0020.397  IL-17, pg/ml15.00(15.00;15.00)15.00(15.00;15.00)0.781  MCP-1, pg/ml1287.20(374.63;2124.20)1014.60(529.10;2683.20)0.537  IL-10, pg/ml14.05(8.78;26.62)33.00(11.60;47.10)0.0180.952  TGF-β1, pg/ml1020.85(245.89;10269.20)423.40(205.00;6450.50)0.515  IL-1RA, pg/ml1678.75(695.58;3536.63)565.70(271.33;1594.93)0.036  IL-8/IL-101.74(0.81;2.45)1.73(1.25;4.05)0.423  IL-8/TGF-β10.03(0.00;0.12)0.12(0.02;0.24)0.054  TNF-α/IL-100.93(0.43;1.23)0.45(0.24;0.80)0.083  TNF-α/TGF-β10.01(0.00;0.06)0.05(0.00;0.09)0.273Data are expressed as median IQR (25%;75%).BALF = Bronchoalveolar lavage fluid; PJP = *Pneumocystis jirovecii* pneumonia; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.The comparison was made by Mann--Whitney U test.P\*:univariate analysis, P^\#^:multivariate analysis.

Comparisons of cytokines and pro-inflammatory/anti-inflammatory cytokine ratios between mixed PJP patients divided into groups by oxygenation index (PaO~2~/FiO~2~), the use of ventilator and outcome {#Sec19}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

There were no significant differences in BALF and blood levels of cytokines and pro-inflammatory/anti-inflammatory cytokine ratios between mixed PJP patients divided into two groups by oxygenation index and the use of ventilator. Compared with survived mixed PJP patients, BALF values of IL-1β, TGF-β1, IL-1β/IL-1RA ratio were significantly higher, and blood levels of TGF-β1 were markedly lower in the deceased ones.

Discussion {#Sec20}
==========

Few studies discussed the difference in outcomes between pure PJP and PJP with concurrent pulmonary infection in non-AIDS immunocompromised patients. Most of the papers were focused on the CMV co-infection in HIV patients. However, the reported effect of concurrent CMV pneumonia on the outcome of AIDS patients with PJP was controversial. Some studies indicated that the morbidity and mortality showed no significant differences between HIV-infected PJP patients with or without concurrent CMV infection \[[@CR12]--[@CR15]\]. In contrast, AIDS patients with PJP who had co-infection with CMV pneumonia in other studies had higher mortality than those with PJP only \[[@CR16], [@CR17]\].

The role of concurrent CMV pneumonia in non-AIDS patients with PJP has not yet been well investigated. Miles et al. reported high mortality in non-HIV PJP patients irrespective of whether they had CMV pneumonia or not \[[@CR15]\], but their case number was limited. Recently, Kim and coworkers reported that concomitant pulmonary CMV infection did not significantly affect the outcome of PJP with respect to the morbidity and mortality in non-HIV-infected patients with PJP \[[@CR18]\]. To the best of our knowledge, this is the first study to compare the outcomes of non-AIDS PJP patients with or without concurrent pulmonary infections, including CMV pneumonia. Our results showed no significant differences in the morbidity and mortality between the two groups of patients (Table [1](#Tab1){ref-type="table"}). Because the studied cases of PJP with concurrent pulmonary infection were limited and CMV pneumonia appeared to be the most common concurrent pulmonary infection, further studies with larger populations are needed to verify these issues.

Theoretically, exaggeration of pro-inflammatory or anti-inflammatory cytokine response may result in excessive inflammation leading to host tissue damage and affect the outcome of the patients. The results of our previous study indicated that as compared with normal lung group, PJP patients had significantly higher levels of pro-inflammatory cytokines and unvaried anti-inflammatory cytokines, and some pro-inflammatory/anti-inflammatory cytokine ratios were of value in assessing the severity of PJP and in predicting the outcome of the patients \[[@CR10]\]. In the current study, the inflammatory cellular responses, as reflected by total cell counts, cell differentials and lymphocyte subpopulation in BALF, between pure PJP and mixed PJP patients showed no significant differences (Table [2](#Tab2){ref-type="table"}). The levels of inflammatory biomarkers in BALF and blood also did not demonstrate significant differences between two groups of patients. An imbalance of pro-inflammatory/anti-inflammatory cytokines was shown to be more exacerbated in mixed PJP than in pure PJP patients (Table [3](#Tab3){ref-type="table"}). However, our results failed to show significant differences in the morbidity and mortality between the two groups. It remains unclear why there should be limited impact of concurrent pulmonary infection on the cell profiles of BALF and related immune responses involved in PJP of non-AIDS immunocompromised patients. Further studies with larger populations are needed to verify these issues.

T helper (Th) 17 cells, a subset of T helper cells, appear to play an important role in fungal clearance and defense \[[@CR19], [@CR20]\]. Impaired IL-17 response was reported to be associated with decreased clearance of Candida and Aspergillus \[[@CR21], [@CR22]\]. However, the role of IL-17 response in pneumocystis infection has not yet been well investigated. The study conducted by Rudner et al. showed decreased levels of IL-17 in the lungs caused by IL-23 deficiency or by neutralizing anti-IL-17 antibody resulted in transient decrease (three weeks after infection) in clearance of pneumocystis organisms in mice \[[@CR23]\]. One previous study suggested that interferon-γ was required to suppress Th17 differentiation, and Th17 response seemed to be ineffective to clear pneumocystis infection in immunocompromised mice \[[@CR24]\]. The only IL-17 study in human subjects indicated that the levels of alveolar lining fluid IL-17 showed no significant difference between PJP infected patients and two PJP free control groups of patients with or without immunosuppression \[[@CR25]\]. However, all the three groups studied included some patients with mixed pulmonary infections. The present study demonstrated that BALF levels of IL-17 in pure PJP and mixed PJP patients were at the lower limit except for one patient and showed no significant difference. Furthermore, the BALF level of IL-17 and IL-23 did not differ between normal controls and either pure PJP or mixed PJP patients (Additional file [3](#MOESM3){ref-type="media"}: Table S3). This is in contrast with the previous study showing the IL-23-IL-17 cytokine axis is involved in murine pneumocystis carinii pneumonia \[[@CR23]\]. The possible reason is that some inhibitors might depress or neutralize the levels of IL-23 and IL-17. Another one is that IL-23 and IL-17 might occur earlier in the disease course and could not be detected later. The roles of IL-23/IL-17 in PJP and mixed PJP with other respiratory infection patients need further studies to explore.

It is of interest to see the effect of concurrent viral or bacterial infection on the immune dysregulation of PJP, and its clinical relevance in the non-AIDS immunocompromised patients with mixed PJP patients. The results showed no significant differences in the variables measured except for that BALF IL-1β/IL-1RA ratio were significantly higher in bacterial infection subgroup (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Because the cases in each subgroup were limited in this study, further studies with larger populations are needed to verify the issues.

Our result showed values of BALF IL-8, IL-8/IL-10 ratio, IL-8/TGF-β1 ratio were significantly higher in pure PJP patients with the neede of mechanical ventilation and in deceased patients (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). After stepwise logistic regression analysis, BALF level of IL-8 was the independent factor for the need of mechanical ventilation and BALF level of IL-8/TGF-β1 ratio was responsible for the death in PJP of non-AIDS immunocompromised patients. Taken together, BALF inflammatory cytokines or inflammatory cytokines/anti-inflammatory cytokine ratios alone may be not strong enough to serve as prognostic factors. Some other factors including the entities of immunosuppression in non-AIDS immunocompromised patients, associated co-morbidity and severity of PJP at the diagnosis may be responsible for the need of mechanical ventilation or death of the patients. Further studies with larger populations are needed to verify these issues.

Despite failing to demonstrate the effect of concurrent pulmonary infection on the outcome of non-AIDS PJP patients, the present study confirmed that immune dysregulation did occur in PJP of non-AIDS immunocompromised patients \[[@CR10]\]. Accordingly, it is highly suggested that steroid treatment may be indicated in the treatment of PJP of non-AIDS immunocompromised patients to damp the immune reconstruction syndrome or immune restoration disease, which is characterized by a condition of acute pulmonary compromise that is associated with return of immune function in immunocompromised patients with pulmonary infection who were clinically stable prior to the return of immune function, caused by pathogens of PJP \[[@CR26], [@CR27]\].

Conclusions {#Sec21}
===========

In summary, concurrent infection may cause more severe immune dysregulation of PJP in non-AIDS immunocompromised patients, but has limited effect on the morbidity and mortality of PJP patients. Because of limited number of cases studied, further studies with larger populations are needed to verify these issues.
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